In a phase 2 trial of peanut oral immunotherapy (OIT) involving 21 adults, 67% achieved maintenance dose tolerance, with the median tolerated dose increasing 100-fold from 30 mg to 3000 mg.

The purpose of this study is to critically evaluate the extent of gastrointestinal adverse effects of varenicline when used at maintenance dose (1 mg twice a day) for smoking cessation.